Xenetic Biosciences Inc. (XBIOW)
Company Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
The company engages in the development of biologic drugs and therapeutics.
It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas.
In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies.
It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez.
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Country | United States |
| IPO Date | Jul 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | James F. Parslow |
Contact Details
Address: No Address available No city data available, Nevada United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | XBIOW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001534525 |
| CUSIP Number | 984015131 |
| ISIN Number | n/a |
| Employer ID | 45-2952962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary |
| Jeffrey F. Eisenberg Esq. | President & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K/A | [Amend] Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 10-K | Annual Report |
| Dec 13, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Dec 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |